The COmBining memantine And cholinesterase inhibitors in Lewy body dementia Treatment (COBALT) trial aimed to determine the clinical and cost effectiveness of 12 months of therapy with up to 20 mg daily oral memantine in addition to acetylcholinesterase inhibitor therapy in people with dementia with Lewy bodies (COBALT-DLB) and Parkinson’s disease dementia (COBALT-PDD) (ISRCTN79794378).20 This evidence concerns the gene BCHE and Lewy body dementia.